H3 BIOMEDICINE
H3 Biomedicine is a privately held, uniquely structured oncology discovery enterprise. At H3, they seek to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue patient-based, genomics-driven, small molecule drugs, which represent the most promising current opportunity in cancer therapeutics.
H3 BIOMEDICINE
Industry:
Biotechnology Genetics Medical
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.h3biomedicine.com
Total Employee:
51+
Status:
Active
Contact:
6172525098
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins IPv6 Contact Form 7
Similar Organizations
Advanced Analytical Technologies
AATI develops, manufactures and markets high-throughput, fully-automated nucleic acid and genetic analysis systems.
Origin
Origin is a privately held, clinical-stage biotechnology company.
Affymetrix
Affymetrix now develops and provides innovative technologies that enable multiplex and parallel analysis of biological systems at the cell,
AIM Biotech
AIM Biotech offers a modular platform to co-culture multiple cell types in discrete 3D and 2D channels.
ArborGen
ArborGen grows and sells pine, eucalyptus and hardwood tree seedlings to the forestry industry.
BaseClear
BaseClear is a contract research laboratory for DNA-based analysis.
Biomatik Corporation
Biomatik Corporation is a full service life sciences products and services company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Codex Genetics
Codex Genetics will first launch the Asian-specific personalized genetic analysis service: SEQ-Me.
Family Tree DNA
Family Tree DNA is a genetic genealogy-based company focused on Y chromosome, autosomal, and mitochondrial ancestry DNA testing.
Haystack Sciences
DNA-enabled medicines for the 21st century.
Switch Biotech AG
SWITCH Biotech uses its broad knowledge and expertise of the molecular biology of the skin to develop drugs for various skin disorders.
ViaGen
ViaGen, a division of Trans Ova Genetics is the industry’s premier source of cloning technology for all non-primate species.
Current Employees Featured
Founder
Official Site Inspections
http://www.h3biomedicine.com Semrush global rank: 1.51 M Semrush visits lastest month: 17.71 K
Unable to get host informations!!!
More informations about "H3 Biomedicine"
H3 Biomedicine - Crunchbase Company Profile
H3 Biomedicine is a privately held, uniquely structured oncology discovery enterprise. At H3, they seek to become a prolific source of new drugs that treat more human cancers with greater success.See details»
Eisai Announces New Executive Leadership Team at H3 …
WOODCLIFF LAKE, N.J., Aug. 30, 2021 /PRNewswire/ -- Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has appointed a new executive …See details»
SCOOP: Eisai closing oncology R&D wing H3 …
Jul 18, 2022 The work at H3 will now be shifted to Eisai’s Deep Human Biology Learning organization. H3 had been plowing ahead with four clinical-stage programs, including lead asset H3B-6545 in a phase 2 ...See details»
H3 Biomedicine - Craft
H3 Biomedicine is a biopharmaceutical company that specializes in cancer genomics. It leverages tumor biology, bioinformatics, and synthetic organic chemistry to create an integrated drug …See details»
Eisai Announces New Executive Leadership Team at H3 …
WOODCLIFF LAKE, N.J., Aug. 30, 2021 /PRNewswire/ -- Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has ...See details»
H3 Biomedicine - VentureRadar
H3 Biomedicine, the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is focused on advancing drugs from bench to... ... Find out ...See details»
H3 Biomedicine Inc. Unveils New Headquarters and Laboratories in ...
Dec 1, 2011 Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as …See details»
Our relentless pursuit of a world without cancer | Eisai US
Sep 14, 2024 Our scientists collaborate across functions while following a biology-first approach—and broadening our horizons allows us to consider the science behind more than just oncology. We call this new organization, and …See details»
H3 Biomedicine Announces Expanded Use of Real …
Feb 11, 2021 Learn more at H3Biomedicine.com. About Eisai Co., Ltd. Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.See details»
Foundation Medicine and H3 Biomedicine Announce …
Feb 24, 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ:FMI) and H3 Biomedicine Inc. today announced a multi-year collaboration for the …See details»
H3 Biomedicine Announces Presentation of Four …
May 20, 2021 CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of four posters ...See details»
EISAI'S U.S. RESEARCH SUBSIDIARY H3 BIOMEDICINE ... - Eisai Co., …
Sep 18, 2013 Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that its U.S. research subsidiary H3 Biomedicine Inc. (Massachusetts, …See details»
H3 Biomedicine Announces Appointment of Chief Medical Officer, …
Feb 19, 2020 H3 Appoints Dr. Antonio Gualberto to Chief Medical Officer. CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & …See details»
Eisai Announces New Executive Leadership Team at H3 Biomedicine
WOODCLIFF LAKE, N.J., Aug. 30, 2021 /PRNewswire/ --Eisai Inc. today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in …See details»
Bristol Myers Squibb - Bristol-Myers Squibb and H3 Biomedicine …
Dec 17, 2018 Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and its U.S.-based precision medicine research & …See details»
H3 Biomedicine Launches to Discover and Develop Next …
Jan 27, 2011 According to the World Health Organization, cancer is the leading cause of death worldwide, accounting for 7.9 million deaths in 2007. Death from cancer is projected to rise, …See details»
H3 Biomedicine Presents Investigational Data ... - Tennessee …
H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of two posters at the 2021 San Antonio …See details»
H3 Biomedicine Presents Investigational Data Update on H3B …
Dec 8, 2021 Learn more at H3Biomedicine.com. Contacts. Media Madeline Davidshofer MacDougall Advisors (781) 235-3078 [email protected]. Release Summary.See details»
H3 Biomedicine, Inc. Presents Data Update on H3B-6545
Dec 8, 2020 Learn more at H3Biomedicine.com. Contacts. Madeline Davidshofer MacDougall (781) 235-3078 Release Summary. H3 Biomedicine, Inc. presents data update on H3B-6545 …See details»
H3 Biomedicine to Present Data from Two Ongoing Precision …
May 16, 2019 Media Inquiries Liz Melone [email protected] 617-256-6622 Release Summary H3 Biomedicine Inc. today announced it will present four posters during the …See details»